World’s first remote gynaecological imaging platform, illumigyn has announced its new distribution agreement with Peramare Pharmaceuticals Nigeria, to deploy 5,000 Gynescopes in Nigeria by 2026, making women’s health care accessible and affordable worldwide.
illumigyn is the first FDA-cleared remote gynaecological platform.
The illumigyn Gynescope™ digitally documents the cervix, vagina, and external genitalia, using high-resolution and superior magnification that enables more accurate pap smears.
In addition, the digital documents are saved to the cloud to be used for remote diagnosis, ongoing medical supervision, and additional consultations, without the need to repeat the procedure.
All Gynescopes connect to a secure cloud system that enables remote analysis and diagnosis.
Yaron Pinchas, Director at Peramare Pharmaceuticals Nigeria said “This agreement is great news for Nigerian women. Nigeria has almost 60 million women that are at risk of developing cervical cancer.
“Every year 12,000 women are diagnosed, and 8,000 – two-thirds of them – die from cervical cancer. We have to stop this trend, and a critical preventative measure is to introduce widely accessible cervical screening with the help of illumgyn.”
Since the Gynescope can be operated by any trained caregiver (OB/GYN, GP, Midwife, Nurse Practitioner, and Physician Assistant) or a nurse practitioner, it opens up the ability for women to be screened and diagnosed even in remote locations without physical access to physicians.
“We established illumigyn to democratize women’s healthcare and to bring advanced gynaecological care to women worldwide – including cervical screening,” said Ran Poliakine, illumigyn’s Founder. “We have signed on to the WHO initiative to eradicate cervical cancer within a generation and are proud to be part of driving change across Africa.”
